169 related articles for article (PubMed ID: 22510778)
1. PPARA: a novel genetic determinant of CYP3A4 in vitro and in vivo.
Klein K; Thomas M; Winter S; Nussler AK; Niemi M; Schwab M; Zanger UM
Clin Pharmacol Ther; 2012 Jun; 91(6):1044-52. PubMed ID: 22510778
[TBL] [Abstract][Full Text] [Related]
2. Direct transcriptional regulation of human hepatic cytochrome P450 3A4 (CYP3A4) by peroxisome proliferator-activated receptor alpha (PPARα).
Thomas M; Burk O; Klumpp B; Kandel BA; Damm G; Weiss TS; Klein K; Schwab M; Zanger UM
Mol Pharmacol; 2013 Mar; 83(3):709-18. PubMed ID: 23295386
[TBL] [Abstract][Full Text] [Related]
3. Expression of CYP3A4 and CYP3A7 in Human Foetal Tissues and its Correlation with Nuclear Receptors.
Betts S; Björkhem-Bergman L; Rane A; Ekström L
Basic Clin Pharmacol Toxicol; 2015 Oct; 117(4):261-6. PubMed ID: 25689036
[TBL] [Abstract][Full Text] [Related]
4. The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin.
Clarke TA; Waskell LA
Drug Metab Dispos; 2003 Jan; 31(1):53-9. PubMed ID: 12485953
[TBL] [Abstract][Full Text] [Related]
5. Effects of atorvastatin on CYP3A4 and CYP3A5 mRNA expression in mononuclear cells and CYP3A activity in hypercholeresterolemic patients.
Willrich MA; Rodrigues AC; Cerda A; Genvigir FD; Arazi SS; Dorea EL; Bernik MM; Bertolami MC; Faludi A; Largura A; Baudhuin LM; Bryant SC; Hirata MH; Hirata RD
Clin Chim Acta; 2013 Jun; 421():157-63. PubMed ID: 23501331
[TBL] [Abstract][Full Text] [Related]
6. Regulation of cytochrome P450 2C9 expression in primary cultures of human hepatocytes.
Sahi J; Shord SS; Lindley C; Ferguson S; LeCluyse EL
J Biochem Mol Toxicol; 2009; 23(1):43-58. PubMed ID: 19202563
[TBL] [Abstract][Full Text] [Related]
7. Factors influencing midazolam hydroxylation activity in human liver microsomes.
He P; Court MH; Greenblatt DJ; von Moltke LL
Drug Metab Dispos; 2006 Jul; 34(7):1198-207. PubMed ID: 16638818
[TBL] [Abstract][Full Text] [Related]
8. Effect of CYP3A4*22, POR*28, and PPARA rs4253728 on sirolimus in vitro metabolism and trough concentrations in kidney transplant recipients.
Woillard JB; Kamar N; Coste S; Rostaing L; Marquet P; Picard N
Clin Chem; 2013 Dec; 59(12):1761-9. PubMed ID: 23974086
[TBL] [Abstract][Full Text] [Related]
9. Drug interaction potential of 2-((3,4-dichlorophenethyl)(propyl)amino)-1-(pyridin-3-yl)ethanol (LK-935), the novel nonstatin-type cholesterol-lowering agent.
Monostory K; Pascussi JM; Szabó P; Temesvári M; Köhalmy K; Acimovic J; Kocjan D; Kuzman D; Wilzewski B; Bernhardt R; Kóbori L; Rozman D
Drug Metab Dispos; 2009 Feb; 37(2):375-85. PubMed ID: 18971317
[TBL] [Abstract][Full Text] [Related]
10. Contribution of cytochrome P450 3A4 and 3A5 to the metabolism of atorvastatin.
Park JE; Kim KB; Bae SK; Moon BS; Liu KH; Shin JG
Xenobiotica; 2008 Sep; 38(9):1240-51. PubMed ID: 18720283
[TBL] [Abstract][Full Text] [Related]
11. Which Genetic Determinants Should be Considered for Tacrolimus Dose Optimization in Kidney Transplantation? A Combined Analysis of Genes Affecting the CYP3A Locus.
Bruckmueller H; Werk AN; Renders L; Feldkamp T; Tepel M; Borst C; Caliebe A; Kunzendorf U; Cascorbi I
Ther Drug Monit; 2015 Jun; 37(3):288-95. PubMed ID: 25271728
[TBL] [Abstract][Full Text] [Related]
12. Drug metabolism of CYP3A4, CYP2C9 and CYP2D6 substrates in pigs and humans.
Thörn HA; Lundahl A; Schrickx JA; Dickinson PA; Lennernäs H
Eur J Pharm Sci; 2011 Jun; 43(3):89-98. PubMed ID: 21447389
[TBL] [Abstract][Full Text] [Related]
13. A human immunodeficiency virus protease inhibitor is a novel functional inhibitor of human pregnane X receptor.
Healan-Greenberg C; Waring JF; Kempf DJ; Blomme EA; Tirona RG; Kim RB
Drug Metab Dispos; 2008 Mar; 36(3):500-7. PubMed ID: 18096673
[TBL] [Abstract][Full Text] [Related]
14. Phenotyping of cytochrome P450 3A enzyme in Gujarat population.
Jani AJ; Rathnam S; Mehta AA
Drug Metab Lett; 2008 Jan; 2(1):5-10. PubMed ID: 19356063
[TBL] [Abstract][Full Text] [Related]
15. Human CYP3A4-introduced HepG2 cells: in vitro screening system of new chemicals for the evaluation of CYP3A4-inhibiting activity.
Araki N; Tsuruoka S; Wang N; Hasegawa G; Yanagihara H; Ando H; Omasa T; Enosawa S; Nagai H; Fujimura A
Xenobiotica; 2008 Nov; 38(11):1355-64. PubMed ID: 18846481
[TBL] [Abstract][Full Text] [Related]
16. Colchicine down-regulates cytochrome P450 2B6, 2C8, 2C9, and 3A4 in human hepatocytes by affecting their glucocorticoid receptor-mediated regulation.
Dvorak Z; Modriansky M; Pichard-Garcia L; Balaguer P; Vilarem MJ; Ulrichová J; Maurel P; Pascussi JM
Mol Pharmacol; 2003 Jul; 64(1):160-9. PubMed ID: 12815172
[TBL] [Abstract][Full Text] [Related]
17. Confirmation that cytochrome P450 2C8 (CYP2C8) plays a minor role in (S)-(+)- and (R)-(-)-ibuprofen hydroxylation in vitro.
Chang SY; Li W; Traeger SC; Wang B; Cui D; Zhang H; Wen B; Rodrigues AD
Drug Metab Dispos; 2008 Dec; 36(12):2513-22. PubMed ID: 18787056
[TBL] [Abstract][Full Text] [Related]
18. Identification of pharmacogenetic predictors of lipid-lowering response to atorvastatin in Chilean subjects with hypercholesterolemia.
Rosales A; Alvear M; Cuevas A; Saavedra N; Zambrano T; Salazar LA
Clin Chim Acta; 2012 Feb; 413(3-4):495-501. PubMed ID: 22120734
[TBL] [Abstract][Full Text] [Related]
19. Cytochrome P450 3A4*22, PPAR-α, and ARNT polymorphisms and clopidogrel response.
Kreutz RP; Owens J; Jin Y; Nystrom P; Desta Z; Kreutz Y; Breall JA; Li L; Chiang C; Kovacs RJ; Flockhart DA
Clin Pharmacol; 2013; 5():185-92. PubMed ID: 24353446
[TBL] [Abstract][Full Text] [Related]
20. Potential impact of steatosis on cytochrome P450 enzymes of human hepatocytes isolated from fatty liver grafts.
Donato MT; Lahoz A; Jiménez N; Pérez G; Serralta A; Mir J; Castell JV; Gómez-Lechón MJ
Drug Metab Dispos; 2006 Sep; 34(9):1556-62. PubMed ID: 16763015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
